AQST · Aquestive Therapeutics
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $4.22
Note written ·
Price against the kill line
7.3% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $4.22, on record since 11 November 2026. The shares are down 8.9% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $4.22, the 200-day average of closes, which would show the shares leading the S&P 500. Full-year 2026 revenue above the top of the $46–50 million guide, or FDA approval of Anaphylm before 16 March 2027, would also show the call wrong.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 3 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 7.6
- Revenue, change on a year (%)
- −41.0
- Gross margin (%)
- 52.3
- Operating margin (%)
- −191.5
- Free cash flow, four quarters ($M)
- −40.7
- Net cash, cash less debt ($M)
- 39.6
- Enterprise value to sales (×)
- 9.3
- Free-cash-flow yield (%)
- −8.3
All filed numbers
What Aquestive Therapeutics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 7.6 | −41.0 | 52.3 | −191.5 |
| first filed | 13.8 | +38.1 | 70.9 | −59.5 |
| first filed | 14.4 | +65.7 | 76.0 | −29.1 |
| first filed | 13.0 | +9.7 | 55.2 | −221.6 |
| first filed | 12.8 | −5.4 | 64.8 | −89.6 |
| first filed | 10.0 | −50.2 | 54.4 | −113.6 |
| Pre-tax income ($M) | −16.5 |
| Net income ($M) four quarters: −79.3 | −16.5 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +13.5 |
| Operating cash flow ($M) | −39.8 |
| Capital spending ($M) | 0.9 |
| Free cash flow ($M) | −40.7 |
| Cash and short-term investments ($M) | 90.3 |
| Debt ($M) non-current long-term debt and finance leases plus current debt | 50.8 |
| Net cash, cash less debt ($M) | 39.6 |
| Deferred revenue ($M) −5.3% on a year | 19.7 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 5.3 |
| Inventory ($M) | 7.3 |
| Shareholders' equity ($M) | −70.8 |
| Market value ($M) | 491 |
| Enterprise value, market value plus net debt ($M) | 452 |
| Enterprise value to sales (×) | 9.3 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | Not meaningful |
| Free-cash-flow yield (%) | −8.3 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 22.0% of shares outstanding sold short, 13.9 days of average trading to cover, −4.0% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $99K | $272K |
| 12 monthsfrom | $99K | $2.4M |
The thesis
Aquestive Therapeutics' shares are more likely to lag the S&P 500 than lead it over the next three months. The FDA decision on Anaphylm, its needle-free epinephrine film, is due on 16 March 2027, after the three-month window, and third-quarter 2026 revenue of $7.6 million fell well short of estimates. That decision date settles the regulatory case; the fourth-quarter revenue report tests the commercial base before it.
The shares closed at $3.57 on 12 November 2026, 47.0% below the intraday 52-week high of $6.74 set on 8 December 2025 and 16.0% lower than the $4.25 close of 14 August 2026. The six closes since 5 November 2026 sit between $3.52 and $3.66, a narrow range after the decline from $4.67 on 13 October 2026.
A director bought shares in the open market on 10 November 2026 (detail under Setup & Price Structure). That is a small vote of confidence from an insider and does not change the timing problem: no approval event falls inside the window.
Bullish and bearish views on Aquestive Therapeutics, Inc.
The bull case on Aquestive Therapeutics, Inc. (AQST), in brief: the FDA accepted the filing as a six-month review. The bear case: third-quarter revenue fell short.
Bull case
- The FDA accepted the filing as a six-month review. The company's 15 October 2026 release reports acceptance of the Anaphylm resubmission as a Class 2 response, with a Prescription Drug User Fee Act (PDUFA) goal date of 16 March 2027. The 3 November 2026 results release says commercial preparations are on track, including a field sales force aimed at allergists.
- The documented deficiency was addressed directly. The FDA's 30 January 2026 Complete Response Letter cited difficulty opening the pouch and placing the film. The company's 17 September 2026 release reports median pouch-opening time cut to 3 seconds from 17 in the repeat human factors study.
- Libervant brings outside cash and two near-dated decisions. Eton Pharmaceuticals licensed Libervant for a $10.0 million upfront fee, up to $47.5 million in milestones and mid-teens royalties, per the 13 October 2026 8-Ks. The company's 3 November 2026 release lists PDUFA dates of 23 March 2027 for ages 12 and older and 29 March 2027 for ages 6 to 11, with Valtoco's orphan exclusivity expiring on 10 January 2027.
- Full-year guidance was affirmed. Revenue guidance of $46–50 million was repeated on 3 November 2026. The finsee.ai earnings review estimates that guidance implies about $12.2 million of fourth-quarter revenue.
- An insider bought at market. Director Richard J. Daly bought 28,025 shares at an average $3.54 on 10 November 2026, per his SEC Form 4 filed 12 November 2026.
Bear case
- Third-quarter revenue fell short. Revenue was $7.557 million against a $11.017 million analyst estimate and down 41% from $12.8 million a year earlier, per the 3 November 2026 results. The company attributed the drop to quarterly swings in Suboxone product orders; manufacturing output was about 26 million doses against about 44 million.
- Losses widened. The third-quarter net loss was $16.5 million, or $0.13 per share, against an estimated $0.11 loss. The adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) loss was $12.2 million, up from $8.6 million a year earlier.
- Cash is shrinking ahead of launch. Cash and equivalents were $90.3 million at 30 September 2026, down from $98.5 million at 30 June 2026. Long-term debt, net, was $50.8 million.
- No approval event falls inside the window. The 16 March 2027 goal date lies beyond the 63-session horizon counted from 12 November 2026, and the shares fell from $4.67 on 13 October 2026 to $3.57 on 12 November 2026 through the Eton licence, the PDUFA announcement and the earnings report.
- Dilution has been a recurring feature. Shares outstanding were 125,687,705 at 30 September 2026 per the results release, after a 27.37% rise in the year to 4 September 2026 per stockanalysis.com.
- The chief executive has been selling. Daniel Barber, President and CEO, sold 25,000 shares at $4.82 on 15 September 2026 and 25,000 at $4.22 on 15 October 2026, both under Rule 10b5-1 pre-arranged plans, per SEC Form 4 filings.
Price setup
The last close of $3.57 on 12 November 2026 is below the 50-day average of closes at $4.4 and below the 200-day average, with the 200-day average a level the shares have not closed above in the recent range. The 52-week closing low is $2.95 on 30 January 2026, the day of the FDA Complete Response Letter, and the intraday 52-week high is $6.74 on 8 December 2025.
Short interest was 18.27% of float, or 7.36 days of trading volume, on 4 September 2026 per stockanalysis.com. That reading is more than two months old.
Management presents at the Jefferies Global Healthcare Conference on 16 November 2026, per the company's 9 November 2026 announcement. Investor one-on-one meetings run through 18 November 2026. No earnings report falls in the next 30 days.
The market has priced in a reduced chance or a delayed payoff: the shares trade 16.0% below their 14 August 2026 close even though the FDA accepted the resubmission on 15 October 2026 with a decision date in March 2027.
Catalysts ahead
- 16 November 2026: Aquestive presents at the Jefferies Global Healthcare Conference at 10:00 am GMT, with investor meetings through 18 November 2026. Management commentary on launch preparation, cash and the FDA review is the next company-controlled update after the third-quarter miss.
- ~31 December 2026 (est.): Health Canada submission for Anaphylm. The company expects the filing in the fourth quarter of 2026; it opens a second market and does not affect the US decision.
- 10 January 2027: Valtoco orphan exclusivity expires. Clears the way for full Libervant approval for ages 12 and older, which gates Eton milestones and royalties payable to Aquestive.
- 16 March 2027: PDUFA goal date for Anaphylm. This is the FDA approval decision, the event that settles the regulatory case.
- 23 March 2027: PDUFA date for Libervant, ages 12 and older. Full approval would turn tentative approval into a marketable product licensed to Eton.
What would change the view
A daily close above $4.22, the 200-day average of closes, which would show the shares leading the S&P 500. Full-year 2026 revenue above the top of the $46–50 million guide, or FDA approval of Anaphylm before 16 March 2027, would also show the call wrong.
What it trades with
The shares trade on company-specific regulatory events and carry little connection to a theme cluster. ARS Pharmaceuticals' neffy, the marketed needle-free epinephrine nasal spray, is the closest read-through for Anaphylm's commercial prospects. Eton Pharmaceuticals is the partner on Libervant, and its disclosures about launch timing feed directly into Aquestive's milestone path.
The evidence, claim by claim (8)
- Third-quarter 2026 revenue was $7.6 million, down 41% from $12.8 million a year earlier; manufacture and supply revenue was $6.7 million and license and royalty revenue $0.8 million. Aquestive Q3 2026 results release · as of
- Third-quarter sales of $7.557 million missed a $11.017 million estimate and loss per share of $0.13 was wider than the $0.11 estimated. Benzinga earnings summary · as of
- Cash and equivalents were $90.3 million and long-term debt, net, was $50.8 million; shares outstanding were 125,687,705. Aquestive Q3 2026 results release · as of
- Full-year 2026 revenue guidance of $46–50 million was affirmed. Aquestive Q3 2026 results release · as of
- The FDA accepted the Anaphylm NDA resubmission as a Class 2 response with a PDUFA goal date of 16 March 2027. Aquestive press release · as of
- Libervant PDUFA dates are 23 March 2027 (ages 12 and older) and 29 March 2027 (ages 6 to 11); Valtoco orphan exclusivity expires 10 January 2027. Aquestive Q3 2026 results release, via BiopharmaWatch · as of
- Director Richard J. Daly bought 28,025 shares in the open market at an average $3.54 on 10 November 2026. SEC Form 4 filed 12 November 2026 · as of
- CEO Daniel Barber sold 25,000 shares at $4.22 on 15 October 2026 under a Rule 10b5-1 plan, after 25,000 at $4.82 on 15 September 2026. SEC Form 4 filings · as of
Sources
- BioPharmaWatch
- Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference · finviz.com
- Aquestive Therapeutics Q3 Revenue Falls 41% Amidst Strategic Pivot to Proprietary Pipeline · panabee.com
- Aquestive Therapeutics (AQST) Q3 2026 earnings review · finsee.ai
- Aquestive Therapeutics Q3 2026 Earnings Call Transcript · webull.com
Related · shared themes
IRON
Disc Medicine
Disc Medicine's shares are modestly favoured to beat the S&P 500 over three months because bitopertin passed its Phase 3 APOLLO trial on 19…
MANE
Veradermics
Veradermics' hair-loss pill VDPHL01 has finished its male trials with clean 12-month safety and cash of $798.4M guided into 2030. The case…
SMMT
Summit Therapeutics
Summit Therapeutics' case rests on FDA approval of ivonescimab in EGFR-mutant lung cancer by the 14 November 2026 goal date. The agency's…
ZLAB
Zai Lab
Zai Lab's shares are modestly more likely to beat the S&P 500 over three months on zoci, its DLL3 cancer drug with an 81.8% first-line…